Tatiana Koudriakova

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15

The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts

Mikhail F. Denissenko, Tatiana Koudriakova, Leslie Smith et al. · Oncogene · 1998 · 106 citations

Aflatoxin B1 Adducts, Hepatology, Oncogenic Agent +7

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Shinji Yamazaki, Judith Skaptason, David Romero et al. · Drug Metabolism and Disposition · 2008 · 94 citations

Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents*

Eugenia Iatsimirskaia, Samir Tulebaev, Elena Storozhuk et al. · Clinical Pharmacology & Therapeutics · 1997 · 82 citations

Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia

Pascal Bonaventure, Jonathan Shelton, Sujin Yun et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 80 citations